


INFORMATION DISCLOSURE CITATION FORM PTO-1449 (Modified) (Use several sheets if necessary)	ATTY. DOCKET NO. 4099-0002.31	SERIAL NO. 09/660,468
	APPLICANT Lau and Wan	
	FILING DATE September 12, 2000	GROUP 1646 / 647



U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
PR	*	4,683,199	07/28/87	Palladino			
	*	4,791,101	12/13/88	Adolf			
	*	5,098,702	03/24/92	Zimmerman, et al.			
	*	5,141,735	08/25/92	Bellemin et al.			
	*	5,248,499	08/28/93	Czarniecki et al.			
	*	5,624,895	04/29/97	Sobel			
	*	5,698,194	12/16/97	Hadden			
	*	5,720,952	02/24/98	Clark et al.			
	*	5,843,423	12/01/98	Lyman et al.			
	*	5,871,725	02/16/99	Schwarz			
	*	5,895,646	04/20/99	Wang			
	*	5,910,303	06/08/99	Takayama et al.			
	*	5,919,443	07/06/99	Michaelis et al.			
	*	6,117,423	09/12/00	Berg			
PR	*	6,165,459	12/26/00	Broxmeyer et al.			


FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chirigos, M.A., et al., "Leukocyte interleukin, inj. (LI) augmentation of natural killer cells and cytolytic t-lymphocytes" <i>Immunopharmacology and Immunotoxicology</i> 17(2):247-264 (1995).
	Pulley, M.S., et al., "Intravenous, Intralesional and Endolymphatic Administration of Lymphokines in Human Cancer" <i>Lymphokine Research</i> 5(supp. 1):S157-S163 (1986).
	Stark, G.R., "Genetic analysis of interferon and other mammalian

David R. 8/24/2

signaling pathways" The Harvey Lectures Series 93:1 16 (1999).	
	
EXAMINER	DATE CONSIDERED
<i>James Rames</i>	<i>8/24/2</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPE 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
MAR 05 2001

REC. CENTER 1600/2300